Clariant Health Care is presenting eight new products in its portfolio of high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines

Clariant will present it latest portfolio of products for the healthcare industry at the upcoming CPHI India tradeshow in Delhi NCR on November 26 - 28, 2024. This year’s event will showcase Clariant Health Care’s Made in India products, local Bonthapally operations, and expertise in biologics, generics, and excipient production. This includes a range of reliable, high-quality, cost-effective, and tailored solutions for the growing Indian healthcare market.

“We are leveraging India’s manufacturing capabilities to provide high-purity excipients to the global pharmaceutical market and our Made in India products are integral to the pharmaceutical sector’s commitment to improving drug formulation, delivery, and patient outcomes. We’re also simultaneously focused on ensuring compliance with the highest industry standards,” comments Vaios Barlas, Global Head of Health Care at Clariant.

Excipients are essential to the stability, bioavailability, and efficacy of active pharmaceutical ingredients (APIs) and the global excipients market is expected to grow at a compound annual growth rate (CAGR) of 6 to 7%. This increase has been driven by rising demand for specialty drugs and biologics, stricter regulatory standards, and the increasing needs of aging populations worldwide.

To ensure the uninterrupted supply of ultra-pure excipients, Clariant has combined the global expertise of Clariant International Ltd (Switzerland) with local manufacturing capabilities in India to offer customized solutions for the evolving needs of the pharmaceutical industry. India is now a global leader in pharmaceutical manufacturing, supplying over 50% of global vaccines and 40% of generic drugs.

“Our customers want high quality products that support local economies and Clariant’s manufacturing operations in India cater to the specialized needs of the Indian and regional markets while also ensuring that we meet the global standards required by the FDA, EMA, and other regulatory bodies. This makes us a preferred partner in the development of biologics, injectables, and complex drug formulations,” says Bhushan Thekedar, Head of Global Business Development, Health Care.